Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry

医学 核医学 前列腺癌 剂量学 泌尿科 放射免疫疗法 药代动力学 前列腺 放射治疗 放射性核素治疗 体内 癌症 放射科 内科学 抗体 免疫学 生物技术 单克隆抗体 生物
作者
Levent Kabasakal,Türkay Toklu,Nami Yeyin,Emre Demirci,Mohammad Abuqbeitah,Meltem Ocak,Aslan Aygün,Emre Karayel,Hüseyin Pehlivanoğlu,Nalan Alan Selçuk
出处
期刊:Molecular Imaging and Radionuclide Therapy [Galenos Yayinevi]
卷期号:26 (2): 62-68 被引量:85
标识
DOI:10.4274/mirt.08760
摘要

OBJECTIVE: The aim of the study was to estimate the radiation-absorbed doses and to study the in vivo and in vitro stability as well as pharmacokinetic characteristics of lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA)-617. METHODS: For this purpose, 7 patients who underwent Lu-177-PSMA therapy were included into the study. The injected Lu-177-PSMA-617 activity ranged from 3.6 to 7.4 GBq with a mean of 5.2±1.8 GBq. The stability of radiotracer in saline was calculated up to 48 h. The stability was also calculated in blood and urine samples. Post-therapeutic dosimetry was performed based on whole body and single photon emission computed tomography/computed tomography (SPECT/CT) scans on dual-headed SPECT/CT system. RESULTS: The radiochemical yield of Lu-177-PSMA-617 was >99%. It remained stable in saline up to 48 h. Analyses of the blood and urine samples showed a single radioactivity peak even at 24 hours after injection. Half-life of the distribution and elimination phases were calculated to be 0.16±0.09 and 10.8±2.5 hours, respectively. The mean excretion rate was 56.5±8.8% ranging from 41.5% to 65.4% at 24 h. Highest radiation estimated doses were calculated for parotid glands and kidneys (1.90±1.19 and 0.82±0.25 Gy/GBq respectively). Radiation dose given to the bone marrow was significantly lower than those of kidney and parotid glands (p<0.05) (0.030±0.008 Gy/GBq). CONCLUSION: Lu-177-PSMA-617 is a highly stable compound both in vitro and in vivo. Lu-177-PSMA-617 therapy seems to be a safe method for the treatment of castration-resistant prostate cancer patients. The fractionation regime that enables the longest duration of tumor control and/or survival will have to be developed in further studies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
haissem完成签到 ,获得积分10
刚刚
1秒前
sjw525完成签到,获得积分10
1秒前
BAEK完成签到 ,获得积分10
2秒前
2秒前
追寻的山晴完成签到,获得积分10
3秒前
852的应助被yy采纳,获得10
3秒前
ppp发布了新的文献求助10
5秒前
胜似闲庭信步完成签到,获得积分10
5秒前
Liii完成签到 ,获得积分10
5秒前
wei发布了新的文献求助10
6秒前
尊敬的驳完成签到,获得积分10
6秒前
JoJo完成签到,获得积分10
8秒前
star完成签到,获得积分10
11秒前
11秒前
小贾完成签到,获得积分10
12秒前
杀死周一完成签到,获得积分10
14秒前
tina酱完成签到 ,获得积分10
16秒前
zhangyiyang完成签到 ,获得积分10
16秒前
隐形骁完成签到,获得积分10
16秒前
17秒前
16601107082发布了新的文献求助10
18秒前
liuchang完成签到 ,获得积分10
18秒前
22336完成签到,获得积分0
18秒前
Lemenchichi完成签到,获得积分10
18秒前
老实的鑫磊完成签到,获得积分20
19秒前
会过期的凤梨完成签到 ,获得积分10
20秒前
hahaha完成签到 ,获得积分10
20秒前
wailwq完成签到 ,获得积分10
21秒前
21秒前
21秒前
怕黑的冰安完成签到,获得积分10
22秒前
大卫戴完成签到 ,获得积分10
22秒前
临天下完成签到,获得积分10
22秒前
小楞楞完成签到,获得积分10
23秒前
tanfor完成签到 ,获得积分10
24秒前
孤星发布了新的文献求助10
24秒前
Matthewwt完成签到,获得积分10
24秒前
hyd完成签到,获得积分10
25秒前
123完成签到,获得积分10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166570
求助须知:如何正确求助?哪些是违规求助? 9559581
关于积分的说明 21750904
捐赠科研通 7757397
什么是DOI,文献DOI怎么找? 3429170
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923